NASDAQ:INFI
Delisted
Infinity Pharmaceuticals Stock News
$0.0160
+0 (+0%)
At Close: Dec 28, 2023
Why Is Infinity Pharmaceuticals (INFI) Stock Up 84% Today?
07:34am, Tuesday, 08'th Aug 2023
Infinity Pharmaceuticals (NASDAQ: INFI ) stock is rocketing higher on Tuesday morning despite a lack of news from the biopharmaceutical company. Investors seeking out news concerning shares of INFI s
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmace
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates
07:04pm, Tuesday, 28'th Mar 2023
Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Infinity Pharmaceuticals (INFI) Report Negative Q4 Earnings? What You Should Know
11:29am, Tuesday, 28'th Mar 2023
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
08:02am, Tuesday, 14'th Mar 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Down 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe for a Turnaround
11:17am, Thursday, 17'th Nov 2022
The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i
Infinity Pharmaceuticals, Inc. (INFI) Q3 2022 Earnings Call Transcript
11:24am, Monday, 14'th Nov 2022
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairma
Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
08:25am, Monday, 07'th Nov 2022
CAMBRIDGE, Mass.
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q2 2022 Results - Earnings Call Transcript
11:03pm, Tuesday, 09'th Aug 2022
Start Time: 16:30 January 1, 0000 4:58 PM ET Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q2 2022 Earnings Conference Call August 09, 2022, 16:30 PM ET Company Participants Adelene Perkins - Chair an
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
08:35am, Tuesday, 17'th May 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage repro
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q1 2022 Results - Earnings Call Transcript
11:16pm, Tuesday, 03'rd May 2022
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman and
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates
09:49pm, Tuesday, 29'th Mar 2022
Infinity (INFI) delivered earnings and revenue surprises of 7.14% and 10.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2021 Results - Earnings Call Transcript
09:30pm, Tuesday, 29'th Mar 2022
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2021 Results - Earnings Call Transcript
Infinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
07:35am, Tuesday, 22'nd Mar 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage repro
Infinity Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
01:35pm, Wednesday, 09'th Mar 2022 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 16th, 2022. 32nd Annual Oppenheimer Healthcare Conference (virtual) Date: March 16t